Galapagos NV (G1LP34)
Market Closed
14 Jul, 19:55
B3 B3 Primary R$
7. 82
0
0%
R$
11.02B Market Cap
- P/E Ratio
- Div Yield
2 Volume
- Eps
R$ 7.82
Previous Close Want to track G1LP34 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
G1LP34 closed Tuesday higher at R$7.82, an increase of 0% from Monday's close, completing a monthly increase of 0.6435% or R$0.05. Over the past 12 months, G1LP34 stock lost -15.4595%.
G1LP34 is not paying dividends to its shareholders.
The last earnings report, released on Oct 22, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Galapagos NV (G1LP34) FAQ
What is the stock price today?
The current price is R$7.82.
On which exchange is it traded?
Galapagos NV is listed on B3.
What is its stock symbol?
The ticker symbol is G1LP34.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 11.02B.
Has Galapagos NV ever had a stock split?
No, there has never been a stock split.
Galapagos NV Profile
| Biotechnology Industry | Healthcare Sector | Henry Gosebruch CEO | B3 Exchange | - ISIN |
| BE Country | 704 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Galapagos NV is a leading biotechnology firm dedicated to discovering and developing innovative medicines, with a focus on oncology and immunology. With its primary operations in the United States and Europe, Galapagos NV has established a significant presence in the biopharmaceutical industry through its commitment to addressing unmet medical needs. The company has formed strategic alliance agreements with major players like Gilead Sciences, Inc. and AbbVie S.à r.l., enhancing its research capabilities and market reach. Founded in 1999 and headquartered in Mechelen, Belgium, Galapagos NV continues to forge ahead in the biotechnology field, underpinned by a robust pipeline of potential breakthrough therapies.
Products and Services
- GLPG3667 - This is a promising candidate that has successfully completed phase 1b trial. The focus of GLPG3667 is on demonstrating safety and efficacy for potential use in treating specific conditions, though the exact therapeutic area is not specified, showing the company's commitment to expanding its portfolio.
- GLPG5101 - A cutting-edge CD19 CAR-T product candidate that is currently under Phase 1/2 trial for relapsed/refractory non-Hodgkin lymphoma. This therapy represents the advancement in cellular immunotherapy, targeting CD19, a protein commonly found on the surface of B cells and involved in many B cell malignancies. What makes GLPG5101 stand out is its point-of-care manufacturing process, which could revolutionize the accessibility and effectiveness of CAR-T therapies.
- GLPG5201 - Similar to GLPG5101, GLPG5201 is also a CD19 CAR-T product candidate but specifically focused on a different indication: relapsed/refractory chronic lymphocytic leukemia. Currently in phase 1/2 trial, GLPG5201 harnesses the same innovative point-of-care manufacturing technology, showing Galapagos' strategic approach to tackling various hematologic malignancies with targeted cellular therapies.
- GLPG5301 - Diversifying its CAR-T portfolio, Galapagos NV presents GLPG5301, a BCMA (B-cell maturation antigen) CAR-T product candidate. This therapeutic is in phase 1/2 trials for relapsed/refractory multiple myeloma, a type of cancer that affects plasma cells. As with its other CAR-T candidates, GLPG5301 is manufactured at the point-of-care, underscoring the company's dedication to developing advanced treatments for complex diseases.
Contact Information
Address: Generaal De Wittelaan L11 A3
Phone: 32 1 534 29 00
Website: https://www.glpg.com
